Wellington Management Group LLP Cuts Position in Krystal Biotech, Inc. $KRYS

Wellington Management Group LLP lessened its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 9.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,599 shares of the company’s stock after selling 1,105 shares during the period. Wellington Management Group LLP’s holdings in Krystal Biotech were worth $1,911,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Brooklyn Investment Group increased its stake in shares of Krystal Biotech by 291.7% in the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company’s stock valued at $25,000 after purchasing an additional 105 shares in the last quarter. Fifth Third Bancorp increased its stake in shares of Krystal Biotech by 159.1% in the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock valued at $31,000 after purchasing an additional 105 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Krystal Biotech in the 4th quarter valued at about $95,000. GAMMA Investing LLC increased its stake in Krystal Biotech by 179.3% during the 1st quarter. GAMMA Investing LLC now owns 673 shares of the company’s stock worth $121,000 after buying an additional 432 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC purchased a new stake in Krystal Biotech during the 1st quarter worth approximately $223,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 13,435 shares of the business’s stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the transaction, the insider directly owned 1,443,276 shares in the company, valued at $216,924,382.80. The trade was a 0.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last 90 days, insiders sold 49,800 shares of company stock worth $7,487,943. Insiders own 13.70% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on KRYS shares. HC Wainwright reiterated a “buy” rating and set a $240.00 price objective on shares of Krystal Biotech in a research note on Friday, August 22nd. Guggenheim cut their price objective on Krystal Biotech from $195.00 to $189.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. Citigroup reiterated a “neutral” rating and set a $166.00 price objective (down from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Chardan Capital cut their price objective on Krystal Biotech from $219.00 to $216.00 and set a “buy” rating for the company in a research note on Friday, August 22nd. Finally, Bank of America cut their price objective on Krystal Biotech from $193.00 to $192.00 and set a “buy” rating for the company in a research note on Tuesday, July 22nd. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, Krystal Biotech presently has a consensus rating of “Moderate Buy” and a consensus target price of $210.38.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock opened at $147.70 on Friday. The stock has a market cap of $4.27 billion, a P/E ratio of 30.02 and a beta of 0.70. The stock’s 50 day simple moving average is $145.83 and its 200-day simple moving average is $154.32. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $207.84.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.21. The business had revenue of $96.04 million for the quarter, compared to analysts’ expectations of $95.42 million. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. As a group, research analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).